The AURKA-specific inhibitor alisertib, currently under clinical evaluation for various cancer types, suppress YAP1 Ser397 phosphorylation and restores cetuximab sensitivity both in vitro and in PDX models, further emphasising the significance of this event in primary resistance to cetuximab (Figs. 3,  5, 6). Here, YAP1 is linked to cancer.